Clinical Characteristics of Hemodialysis Patients with COVID-19 Referred to Hemodialysis Centers Affiliated with the Shahrekord University of Medical Sciences Between 2020 and 2021

Jundishapur Journal of Chronic Disease Care

article

Nilofar Salehi¹  Seyed Mojtaba Sohrevardi²  Shahriyar Salehi Tali⁴  Golnaz Afzal² 

[1] Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences;Clinical Pharmacy, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences;Stroke Prevention and Atherosclerosis Research Centre, University of Western Ontario;School of Nursing and Midwifery, Community-Oriented Nursing Midwifery Research Center, Shahrekord University of Medical Sciences

关键词: Chronic Kidney Disease;    Hemodialysis;    COVID-19;   

DOI  :  10.5812/jjcdc-135670

来源: Kowsarmedical

【 摘 要 】

Background: The coronavirus pandemic (COVID-19) seriously threatens the health and life of people with underlying diseases, suchas patients undergoing hemodialysis.Objectives: This study aimed to determine the clinical characteristics of COVID-19 patients with chronic kidney disease undergoinghemodialysis referring to hemodialysis centers affiliated with the Shahrekord University of Medical Sciences between 2019 and 2021.Methods: This was a retrospective descriptive-analytical study with a sample size of 144 hemodialysis patients with COVID-19. Thedata were collected by a demographic questionnaire, a checklist based on the presence of underlying diseases, the cause of thekidney failure, drugs received during hemodialysis, medications used for COVID, the result of COVID-19 treatment, and outpatientor inpatient treatment, and the checklist of laboratory indices extracted from the patient’s medical records. Data were analyzed bySPSS version 20 and descriptive and analytical statistical tests.Results: The average age was 57.2 ± 14.42 years, and 64.6% were men, 35.4% were women, 64.6% recovered, and 35.4% died, although42.4% of patients were treated on an outpatient basis, and 57.6% needed hospitalization. Also, 93.7% of patients were vaccinated.The average duration of hemodialysis treatment was 6.44 years, and diabetes accounted for 31.1% of the causes of kidney failure, andthese people had a higher chance of mortality. Positive c-reactive protein (CRP) results were found in 72.2% of patients, and 54.2% hada positive erythrocyte sedimentation rate (ESR). In addition, 22.2% of patients used mechanical ventilation, and 88.2% had positivePCR results. Iron, ferritin, albumin, and hemoglobin index were lower than normal in all patients. Patients with positive hepatitis Bantigens were treated with sofosbuvir. In outpatient treatment, 65.6% used remdesivir, and 70.5% used dexamethasone. Regardinginpatient treatment, 75.9% used methylprednisolone, 56.6% used tocilizumab, and 54.2% used pirfenidone.Conclusions: The rate of death and hospitalization in hemodialysis patients with COVID-19 was higher than that of normal people.Diabetes increases the chance of morbidity and mortality of COVID-19 in hemodialysis patients. The reduction of hemoglobin, iron,ferritin, and albumin weakened the therapeutic response of hemodialysis patients to COVID-19 and increased the chance of death.Although various drugs were used in the treatment of COVID-19 hemodialysis patients, the patients did not follow a single regimen.

【 授权许可】

Unknown